Modus Therapeutics’ Annual General Meeting on 17 May 2024 resolved in accordance with the following:

  • That no dividend would be paid.
  • To discharge the board members and the managing director from liability with respect to their management of the company for the financial year 2023.
  • That the board of directors shall comprise three board members without any deputies.
  • To re-elect the board members Viktor Drvota, Ellen Donnelly and Torsten Goesch and to re-elect Viktor Drvota as the chairman of the board.
  • To re-elect Ernst & Young Aktiebolag as auditor.
  • To adopt principles for the Nomination Committee, in accordance with the Nomination Committee’s proposal.
  • To amend the company’s articles of association in order to increase the limits of the company’s share capital and number of shares, whereby the share capital shall be not less than SEK 1,440,000 and not more than SEK 5,760,000, and the number of shares shall be not less than 24,000,000 and not more than 96,000,000.
  • To authorize the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares, convertibles and/or warrants.
  • To authorize the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, to on behalf of the company enter into exit bonus agreements with senior executives and other key persons for the purpose of retaining such persons and to offer the appropriate incentives in relation to the continued development of the company.

For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments
Annual General Meeting in Modus Therapeutics Holding AB (publ)

© Modular Finance, source Nordic Press Releases